Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2043609 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A4KCNH2SCN3ASLC6A2 | |
| SCHEMBL2041148 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A4KCNH2SCN3ASLC6A2 | |
| SCHEMBL31134235 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A4KCNH2SCN3ASLC6A2 | |
| SCHEMBL2041146 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A4KCNH2SCN3ASLC6A2 | |
| SCHEMBL2584119 | 0.91 | SLC6A3 (0.48) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14763450 | 0.91 | SLC6A3 (0.44) | SLC6A3SLC6A4 | |
| SCHEMBL24491224 | 0.86 | KCNH2 (0.46) | KCNH2SCN3A | |
| SCHEMBL8698715 | 0.86 | SLC6A3 (0.49) | SLC6A3SLC6A4KCNH2SCN3ASLC6A2 | |
| SCHEMBL8698718 | 0.86 | SLC6A3 (0.49) | SLC6A3SLC6A4KCNH2SCN3ASLC6A2 | |
| SCHEMBL8694988 | 0.85 | KCNH2 (0.48) | KCNH2SCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024200777-A1 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-10-03 | — | — | WO | disclosed |